Skip to content

Good virological outcome in patients starting HIV therapy in the UK

Raltegravir receives accelerated approval from the FDA

Stigma surrounding genital herpes a major barrier to disclosure, UK study finds

Studies underway to find the best time to start anti-HIV therapy in those taking TB treatment

Sudden increases in viral load in first two years of infection could indicate superinfection

New Swedish chlamydia strain ‘possible emerging threat to public health’

HIV-related symptoms significantly reduced three weeks after quitting smoking

Kenya: treatment literacy lagging behind ARV rollout

Uganda: factory to boost ARV rollout